Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 147 clinical trials
Advancing Cardiac Care Unit-based Rapid Assessment and Treatment of hypErcholesterolemia (ACCURATE)

ACCURATE will test the hypothesis that opportunistic genetic testing for Familial Hypercholesterolemia (FH) in patients admitted to hospital with an acute coronary syndrome will increase the

cholesterol level
LDL Cholesterol
genetic analysis
lipid-lowering therapy
acute coronary syndrome
  • 23 Mar, 2022
  • 1 location
Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia

evaluate the tolerability and safety of multiple-dose repeated administration of IBI306 in the Chinese population with hypercholesterolemia, and to recommend the dose for the second phase. The main purpose

  • 10 Jul, 2021
  • 1 location
Statins in Reducing Events in the Elderly (STAREE) Heart Sub-study

The STAREE-HEART sub-study will examine the effect of statin treatment over a 3-year period compared with placebo on markers of cardiac ageing. This will include determining global longitudinal strain with transthoracic echocardiography, atrial fibrillation with home measures twice daily for two weeks and changes in biomarkers.

diagnostic procedure
12 lead ECG
hmg-coa reductase inhibitors
heart study
  • 26 Jan, 2021
  • 1 location
Left Ventricular Hypertrophy Reduction With Statins in Hypertensive Patients

Experimental studies have showed that statins reduce left ventricular hypertrophy. The main objective is to observe the reduction of left ventricular hypertrophy with statins in hypertensive patients. The hypothesis is that patients treated with statins will have a reduction of at least 10% compared with patients treated only with antihypertensive …

left ventricular hypertrophy
  • 07 Nov, 2020
  • 1 location
Genetic Testing and Motivational Counseling for FH

To date, there are highly effective lipid-lowering drugs, the combination of which makes it possible to achieve the target level of LDL-C in most patients with familial hypercholesterolemia (FH

cholesterol level
  • 01 Nov, 2021
  • 1 location
Lipid Management in Renal Transplant Recipients Using Evolocumab.

Cardiovascular disease is the leading cause of mortality after renal transplantation, accounting for more than 30% of deaths. Elevated lipid levels (hyperlipidemia) are a frequent finding following transplantation and the immunosuppressive medications play a central role in the development or worsening of hyperlipidemia. In the general population, the correlation between …

  • 22 Jul, 2022
  • 1 location
The Use of Mobile Health Technology and Behavioral Economics to Encourage Adherence in Adolescents

Familial hypercholesterolemia (FH) affects over one million Americans and increases the risk of cardiovascular disease (CVD) by as much as 20-fold. Although the use of statins can substantially

genetic analysis
cardiovascular disease
  • 23 Jul, 2022
  • 1 location
Statin Therapy in Patients With Early Stage ADPKD

approved by the Food and Drug Administration (FDA) for adults for treatment of hyperlipidemia (high cholesterol levels). The investigators are using pravastatin in this study as an investigational drug for

glomerular filtration rate
investigational drug
renal disease
  • 21 Mar, 2022
  • 1 location
The Combined Portfolio Diet and Exercise Study (PortfolioEx)

The purpose of this study is to determine whether a dietary portfolio of cholesterol-lowering foods (viscous fibres, soy protein, plant sterols and nuts) further enhanced by increased levels of monounsaturated fatty acids (MUFA) and low glycemic index foods; together with a structured exercise program reduce the progression of carotid and …

fatty acids
low density lipoprotein
percutaneous coronary intervention
  • 24 Feb, 2022
  • 1 location
Compare the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy Versus Rosuvastatin Monotherapy in Korean Patients With Left Ventricular Diastolic Dysfunction and Hyperlipidemia

preserved left ventricular ejection fraction (LVEF 50%) and are accompanied by dyslipidemia (LDL 100 mg / dl) will be enrolled. Only patients who do not meet the exclusion criteria should be enrolled in the study. Once the patient is selected, the patient is informed of the study and receives the …

  • 03 Feb, 2021
  • 1 location